ENCell Co., Ltd. (KOSDAQ:456070)
South Korea · Delayed Price · Currency is KRW 5,900.00
-70.00 (-1.17%)
Sep 22, 2026, 3:30 PM KST
ENCell Revenue
ENCell had revenue of 868.01M KRW in the quarter ending June 30, 2026, a decrease of -26.29%. This brings the company's revenue in the last twelve months to 4.16B, down -28.59% year-over-year. In the year 2025, ENCell had annual revenue of 5.26B, down -27.06%.
Revenue (ttm)
4.16B
Revenue Growth
-28.59%
P/S Ratio
15.63
Revenue / Employee
n/a
Employees
n/a
Market Cap
65.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.26B | -1.95B | -27.06% |
| Dec 31, 2024 | 7.21B | -3.32B | -31.51% |
| Dec 31, 2023 | 10.53B | 3.16B | 42.87% |
| Dec 31, 2022 | 7.37B | 3.46B | 88.49% |
| Dec 31, 2021 | 3.91B | 2.50B | 178.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| Prestige BioPharma | 16.21B |
| GeneOne Life Science | 12.37B |
| Anterogen.Co.,Ltd. | 8.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.99B |